Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) consisting of the antibody Belantamab, the ADC cytotoxic payload Monomethyl auristatin F, and the linker Maleimido-caproyl. Belantamab mafodotin enhances immune cell infiltration and activation within tumors and delays tumor growth that can be used in studies of multiple myeloma.

玛贝兰妥单抗, GSK2857916, GSK 2857916, Belantamab mafodotin-blm

Human

ELISA FCM Functional assay

Monoclonal

Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.

< 1 EU/mg

Human IgG1 kappa-mcMMAF

ADC Control Human IgG1-mcMMAF

Antibody: Belantamab

Linker: Maleimido-caproyl

Payload: Monomethyl auristatin F

CHO

608

Q02223

TNFRSF17/BCMA/CD269

149.76 kDa (Predicted)